Last edition
News about "Dave Fredrickson"
EU Approves Imfinzi as First Perioperative Immunotherapy for Gastric and Gastroesophageal Cancers
The EU approval of Imfinzi is based on phase-III MATTERHORN trial results, which showed significant improvements in event-free and overall survival in early-stage gastric and gastroesophageal cancer patients.
Dave Fredrickson | 17/03/2026 | By Akanki
FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.
Dave Fredrickson | 23/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy